HMGCR and cancer: A number of studies have shown that use of cholesterol-lowering statin drugs, which inhibit the rate limiting enzyme in cholesterol synthesis, HMG-CoA reductase, reduce the risk of advanced PCa, especially when used for more than 5 years, and usually many years prior to any evidence of cancer [15], [17], [18], [19], [20], [22], [23], [24].